#VisualAbstract: Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer

1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months).

2. 1% of patients in each group experienced treatment-related mortality.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Limited evidence exists on combined PD-1 and HER2 blockade with chemotherapy in HER2-positive gastro-esophageal cancer. This randomized controlled trial aimed to assess the safety and efficacy of adding pembrolizumab or placebo to the current standard-of-care (fluorouracil plus cisplatin or capecitabine plus oxaliplatin) among patients with HER2-positive gastric or gastro-esophageal cancer. The primary outcome was progression-free survival, while the key secondary outcome was overall survival. According to study results, pembrolizumab significantly improved progression-free survival compared to placebo, particularly in tumours with PD-L1 combined score above 1. Although well done, this study was limited by ongoing overall survival follow-up and the need for final analysis.

Click to read the study in The Lancet

RELATED REPORTS

World Health Organization warns that one in six infections now antibiotic resistant

Increasing cancer incidence rates in younger and older adults worldwide

Punjab launches AI screening program this week

Relevant Reading: Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

In-depth [randomized-controlled trial]: Between Oct 5, 2018, and Aug 6, 2021, 1327 patients were screened for eligibility across 168 medical centers in 20 countries. Included were patients ≥ 18 years with metastatic HER2-positive gastro-esophageal cancer, lacking prior treatment. Altogether, 698 patients (350 in pembrolizumab and 348 in placebo) were included in the final analysis. The primary outcome of progression-free survival significantly favoured pembrolizumab (10.0 vs. 8.1 months, hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.61–0.87, p=0.0002). The secondary outcome of overall survival showed improvement but did not meet the significance criteria (20.0 vs. 16.8 months, HR 0.84, 95% CI 0.70–1.01, p=0.084). Most adverse events were mild-to-moderate with 1% of patients in each group experiencing mortality. Findings from this study suggest that pembrolizumab, added to trastuzumab and chemotherapy, enhances progression-free survival in HER2-positive gastro-esophageal cancer.

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.